Mavacamten For Use In The Treatment Of Hypertrophic Cardiomyopathy
Patent No. EP3661514 (titled "Mavacamten For Use In The Treatment Of Hypertrophic Cardiomyopathy") was filed by Myokardia on Aug 3, 2018. The application was issued on Sep 17, 2025.
Patent Summary
Compound 1, or a pharmaceutically acceptable salt thereof, is used to treat hypertrophic cardiomyopathy (HCM) and myocardial diastolic dysfunction. The method comprises administering a therapeutically effective amount, specifically a total daily dosage of 2 mg to 15 mg ± 10%, including specific doses of 2.5 mg, 5 mg, 10 mg, or 15 mg. Treatment may target obstructive HCM (oHCM) with LVOT gradients ≥30 mmHg or non-obstructive HCM and HFpEF. Efficacy is associated with maintaining blood plasma concentrations typically between 200 and 750 ng/mL (optimally 350–700 ng/mL). Dosage may be adjusted based on plasma levels, subject weight (e.g., 10 mg for ≤60 kg; 15 mg for >60 kg), or changes in left ventricular ejection fraction (LVEF). Compound 1 may be administered concomitantly with beta-blockers.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
EP3661514
- Application Number
- EP18759209A
- Filing Date
- Aug 3, 2018
- Status
- Granted And Under Opposition
- Aug 15, 2025
- Publication Date
- Sep 17, 2025
- External Links
- Slate, Register , Google Patents